BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces a change to the presentation time of the Company’s oral virtual presentation at the upcoming Next Gen Immuno-Oncology Congress.
June 24, 2020
· 4 min read